Trial Profile
An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- Sponsors Roche
- 09 Mar 2023 Status changed from not yet recruiting to completed.
- 09 Feb 2018 Planned initiation date changed from 12 Dec 2017 to 28 Feb 2018.
- 01 Dec 2017 Planned initiation date changed from 20 Nov 2017 to 12 Dec 2017.